title: SUMO wrestling with Ras.
abstract: This review discusses our current understanding of the small ubiquitin-like modifier (SUMO) pathway and how it functionally intersects with Ras signaling in cancer. The Ras family of small GTPases are frequently mutated in cancer. The role of the SUMO pathway in cancer and in Ras signaling is currently not well understood. Recent studies have shown that the SUMO pathway can both regulate Ras/MAPK pathway activity directly and support Ras-driven oncogenesis through the regulation of proteins that are not direct Ras effectors. We recently discovered that in Ras mutant cancer cells, the SUMOylation status of a subset of proteins is altered and one such protein, KAP1, is required for Ras-driven transformation. A better understanding of the functional interaction between the SUMO and Ras pathways could lead to new insights into the mechanism of Ras-driven oncogenesis.
authors.affiliation: a Laboratory of Canter Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda , MD , USA.
authors.forename: Haibo
authors.initials: H
authors.lastname: Zhang
authors.affiliation: a Laboratory of Canter Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH , Bethesda , MD , USA.
authors.forename: Ji
authors.initials: J
authors.lastname: Luo
mesh_terms: D000818:Animals; D006801:Humans; D025842:SUMO-1 Protein / Q000378:metabolism*; D058207:Sumoylation; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D025842:SUMO-1 Protein; D018631:ras Proteins
keywords: KAP1; KRAS; SUMO; colorectal cancer; non-oncogene addiction